Newtown, PA, United States of America

Shuqun Lin

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 103(Granted Patents)


Location History:

  • Newtown, NJ (US) (2019)
  • Newtown, PA (US) (2008 - 2020)

Company Filing History:


Years Active: 2008-2020

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: Innovations of Shuqun Lin in Modulating Immune Responses

Introduction

Shuqun Lin is a prominent inventor based in Newtown, PA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 15 patents to his name, Lin has focused on developing compounds that modulate immune responses, particularly in relation to IL-12, IL-23, and IFN alpha.

Latest Patents

Among his latest patents are the amide-substituted heterocyclic compounds that serve as modulators of IL-12, IL-23, and/or IFN alpha responses. These compounds are characterized by a specific formula and include stereoisomers or pharmaceutically acceptable salts. They are designed to act on Tyk-2, leading to signal transduction inhibition, which is crucial for therapeutic applications in immune modulation.

Career Highlights

Shuqun Lin is currently associated with Bristol-Myers Squibb Company, where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding of immune modulation and its applications in treating various diseases.

Collaborations

Lin has collaborated with notable colleagues such as Stephen T. Wrobleski and John S. Tokarski, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shuqun Lin's work exemplifies the intersection of scientific research and practical application in the pharmaceutical industry. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…